These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 6166376)
1. Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer. Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT Cancer Treat Rep; 1981; 65(7-8):715-7. PubMed ID: 6166376 [No Abstract] [Full Text] [Related]
2. Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung. Eagan RT; Frytak S; Ingle JN; Creagan ET; Nichols WC; Kvols LK Cancer Treat Rep; 1980; 64(8-9):925-8. PubMed ID: 7192602 [TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. Jordan WM; Valdivieso M; Frankmann C; Gillespie M; Issell BF; Bodey GP; Freireich EJ Cancer Treat Rep; 1981; 65(3-4):197-205. PubMed ID: 6786737 [No Abstract] [Full Text] [Related]
4. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK Cancer Treat Rep; 1981; 65(5-6):453-8. PubMed ID: 6263477 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Kelsen D; Gralla R; Stoopler M; Casper E; Cheng E; Kosloff C; Golbey R Cancer Treat Rep; 1982 Feb; 66(2):247-51. PubMed ID: 7034932 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, vincristine, lomustine, cisplatin, and doxorubicin in the treatment of non-small cell lung cancer. Pearlman NW; Meyers TJ; Siebert PE; Wallner SF; Carson SD; Campbell DN; Johnson FB; Kennaugh R; Rempel P Cancer Treat Rep; 1983 Apr; 67(4):375-6. PubMed ID: 6303587 [TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer. Knost JA; Greco FA; Hande KR; Richardson RL; Fer MF; Oldham RK Cancer Treat Rep; 1981; 65(11-12):941-5. PubMed ID: 7028255 [TBL] [Abstract][Full Text] [Related]
8. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. van Slooten H; van Oosterom AT Cancer Treat Rep; 1983 Apr; 67(4):377-9. PubMed ID: 6687835 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. Eagan RT; Frytak S; Creagan ET; Ingle JN; Kvols LK; Coles DT Cancer Treat Rep; 1979; 63(9-10):1589-91. PubMed ID: 227597 [No Abstract] [Full Text] [Related]
10. Four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group Pilot Study. Livingston RB; Mira J; O'Bryan RM Cancer Treat Rep; 1981; 65(1-2):143-4. PubMed ID: 6164484 [No Abstract] [Full Text] [Related]
11. CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung. Cambareri RJ; Smith FP; Macdonald JS; Haidak DJ; Ueno WM; Hoth DH; Woolley PV; Schein PS Cancer Treat Rep; 1981; 65(3-4):317-20. PubMed ID: 6263471 [No Abstract] [Full Text] [Related]
12. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer. Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK Cancer Treat Rep; 1981; 65(5-6):517-9. PubMed ID: 7195306 [No Abstract] [Full Text] [Related]
13. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up. Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811 [TBL] [Abstract][Full Text] [Related]
14. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer. Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298 [No Abstract] [Full Text] [Related]
15. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S; Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326 [TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer. Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951 [No Abstract] [Full Text] [Related]
17. [Pilot study of sequential chemotherapy and radiation therapy using of liniac and fast neutron for limited small cell lung cancer]. Takiguchi Y; Nagao K; Miyamoto T; Takamura M; Yasukawa T; Kuriyama T Gan To Kagaku Ryoho; 1995 Jun; 22(7):957-9. PubMed ID: 7794004 [No Abstract] [Full Text] [Related]
19. Scheduled and unscheduled combination chemotherapy in the treatment of squamous cell lung cancer (cyclophosphamide, adriamycin, vincristine and bleomycin, with and without cis-platinum). Jones DH; Bleehen NM; Grant RM; Plowman PN; Roberts JT; Sikora K; Watson JV; Wiltshire CR Anticancer Res; 1983; 3(4):235-8. PubMed ID: 6192751 [TBL] [Abstract][Full Text] [Related]
20. [Comparative study of 2 different chemotherapeutic combinations in epidermoid carcinoma of the lung. Preliminary results]. Pipino G; Germiniani R; Maione G; Fazio FM Arch Sci Med (Torino); 1983; 140(2):135-8. PubMed ID: 6192792 [No Abstract] [Full Text] [Related] [Next] [New Search]